BioCardia, Inc. (BCDA)

Over the past six months, BioCardia, Inc.'s stock has declined by 27.41%. Key events include a net loss reported in Q2 2025 and a limited cash runway, an announcement regarding the registration of shares for potential resale, and the closing of a $6.0 million financing. The company regained compliance with Nasdaq Capital Market's Listing Requirements. A net loss was reported in Q3 2025, but the company has a cash runway into Q2 2026. Enrollment of the first patients in the Phase 3 CardiAMP HF II pivotal study was announced, and BioCardia announced a positive preliminary clinical consultation with Japan's PMDA.

BioCardia, Inc.'s products and services are primarily investigational therapies and specialized delivery systems, so traditional demand seasonality is not applicable. Demand is driven by clinical trial progression, regulatory approvals, and the prevalence of the diseases they aim to treat.

BioCardia, Inc. is a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Their lead product, the CardiAMP® Autologous Mononuclear Cell Therapy System, is in Phase III trials for ischemic heart failure and refractory angina. The CardiALLO™ Allogeneic Mesenchymal Stem Cell Therapy Platform is in Phase I/II trials for ischemic heart failure and ARDS. The Helix™ Biotherapeutic Delivery System is a proprietary transendocardial delivery system, and Morph® Deflectable Guides and Sheaths Products enhance delivery precision.

BioCardia, Inc. is headquartered in Sunnyvale, California, and primarily focuses its development and clinical trial activities within the United States. The company is also engaged in regulatory preparations and consultations with the Japan PMDA for its CardiAMP® Cell Therapy.

BioCardia's brand reputation appears generally positive, with MarketBeat indicating a higher score than 75% of companies in the medical sector. Recent news highlights include the addition of Farhan Shahab as Vice President of Quality. Ongoing progress in clinical trials and positive consultations with regulatory bodies contribute to a favorable perception.

BioCardia, Inc. has 28 institutional owners and shareholders holding a total of 458,990 shares, including CM Management, LLC and Vanguard Group Inc. Notable individual insider holders include Steven Jerry Glauser, Kimberly Stertzer, and Peter Altman.